|
Mentor Corporation announced today that subject enrollment and initial dosing in its pivotal Phase IIIb study of its investigational botulinum toxin type A for the reduction of glabellar rhytides (frown lines) by intramuscular injection has been completed
SANTA BARBARA, CA, USA | January 29, 2008 | Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetic market, announced today that subject enrollment and initial dosing in its pivotal Phase IIIb study of its investigational botulinum toxin type A for the reduction of glabellar rhytides (frown lines) by intramuscular injection has been completed. Enrollment in the IIIb trial, which consisted of 700 subjects, began in late November and was completed in mid January.
Joshua H. Levine, President and Chief Executive Officer of Mentor Corporation, commented, "We are very excited about the rapid completion of subject enrollment in Phase IIIb of our botulinum toxin clinical trial. Our investigators observed strong subject interest in the study drug and this leads us to believe that the market is primed for new products focused on the large and rapidly growing cosmetic application."
"Based on my participation in these clinical studies, I am very impressed with the results I am seeing with this new formulation of botulinum toxin," said Dr. Joel Schlessinger, a board certified physician in dermatology and cosmetic surgery and President emeritus of American Society of Dermatology and current President of Aesthetic Surgery. He further stated "there is a significant amount of interest and excitement about new products being developed for the cosmetic indication focused on the reduction of glabellar rhytides (frown lines)."
About Mentor Corporation
Founded in 1969, Mentor Corporation is a leading supplier of medical products for the global aesthetic market. The Company develops, manufactures and markets innovative, science-based products for surgical and non-surgical medical procedures that allow patients to retain a more youthful appearance and improve personal well-being. The Company's website is www.mentorcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding clinical studies and regulatory activities for Mentor's botulinum toxin type A product candidate. These forward-looking statements are based on our current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by us. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements speak only as of the date hereof and are based upon the information available to us at this time. Such information is subject to change, and we will not necessarily inform you of such changes. These statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statement as a result of various factors.
The Securities and Exchange Commission filings of Mentor, including, without limitation, its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and recent Current Reports on Form 8-K, discuss important risk factors that could contribute to such differences or otherwise affect its business, results of operations and financial condition. Mentor undertakes no obligation to revise or update publicly any forward-looking statement for any reason.
SOURCE: Mentor Corporation
|
